284 related articles for article (PubMed ID: 2647312)
41. In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.
Gaver RC; George AM; Deeb G
Cancer Chemother Pharmacol; 1987; 20(4):271-6. PubMed ID: 3319277
[TBL] [Abstract][Full Text] [Related]
42. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
Siddik ZH; Newell DR; Boxall FE; Harrap KR
Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
[TBL] [Abstract][Full Text] [Related]
43. Clinical pharmacokinetics and administration of established platinum drugs.
O'Dwyer PJ; Stevenson JP; Johnson SW
Drugs; 2000; 59 Suppl 4():19-27. PubMed ID: 10864227
[TBL] [Abstract][Full Text] [Related]
44. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
45. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group.
DeGregorio MW; Lum BL; Holleran WM; Wilbur BJ; Sikic BI
Cancer Chemother Pharmacol; 1986; 18(3):235-8. PubMed ID: 3542268
[TBL] [Abstract][Full Text] [Related]
46. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
47. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy.
Goel R; Andrews PA; Pfeifle CE; Abramson IS; Kirmani S; Howell SB
Eur J Cancer; 1990 Jan; 26(1):21-7. PubMed ID: 2156545
[TBL] [Abstract][Full Text] [Related]
49. Determination of platinum originated from antitumoral drugs in human urine by atomic absorption spectrometric methods.
da Costa AC; Vieira MA; Luna AS; de Campos RC
Talanta; 2010 Oct; 82(5):1647-53. PubMed ID: 20875558
[TBL] [Abstract][Full Text] [Related]
50. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
51. Platinum pharmacokinetics in sulphur-crested cockatoos (Cacatua galerita) following single-dose cisplatin infusion.
Filippich LJ; Bucher AM; Charles BG
Aust Vet J; 2000 Jun; 78(6):406-11. PubMed ID: 10920780
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits.
Kizu R; Higashi S; Kidani Y; Miyazaki M
Cancer Chemother Pharmacol; 1993; 31(6):475-80. PubMed ID: 8453687
[TBL] [Abstract][Full Text] [Related]
53. A sensitive postcolumn derivatization/UV detection system for HPLC determination of antitumor divalent and quadrivalent platinum complexes.
Kizu R; Yamamoto T; Yokoyama T; Tanaka M; Miyazaki M
Chem Pharm Bull (Tokyo); 1995 Jan; 43(1):108-14. PubMed ID: 7895301
[TBL] [Abstract][Full Text] [Related]
54. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors.
Dominici C; Petrucci F; Caroli S; Alimonti A; Clerico A; Castello MA
J Clin Oncol; 1989 Jan; 7(1):100-7. PubMed ID: 2909663
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetic evaluation of zeniplatin in humans.
DeMarco LC; Budman DR; Lathia C; Amorusi P; Birkhofer M; Lichtman S; Weiselberg L; Vinciguerra V; Lovecchio J; Gal D
Cancer Chemother Pharmacol; 1995; 36(1):35-40. PubMed ID: 7720173
[TBL] [Abstract][Full Text] [Related]
56. Use of microdialysis to study platinum anticancer agent pharmacokinetics in preclinical models.
Johansen MJ; Thapar N; Newman RA; Madden T
J Exp Ther Oncol; 2002; 2(3):163-73. PubMed ID: 12415633
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Figg WD; Christian MC; Lush R; Link CJ; Davis P; Kohn E; Sarosy G; Rothenberg ML; Weiss RB; Ryan N; Jacobs J; Reed E
Biopharm Drug Dispos; 1997 May; 18(4):347-59. PubMed ID: 9158882
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
[TBL] [Abstract][Full Text] [Related]
59. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.
Newell DR; Siddik ZH; Gumbrell LA; Boxall FE; Gore ME; Smith IE; Calvert AH
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1399-405. PubMed ID: 3315699
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of platinum following the administration of cis-(glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in dogs.
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1997; 17(5A):3681-3. PubMed ID: 9413223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
